Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer

References

• Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003; 9: 3700–4
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735–43
   PubMed Web of Science ®Google Scholar
• Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2007; 120: 694–701
   PubMed Web of Science ®Google Scholar
• Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371–6
   PubMed Web of Science ®Google Scholar
• Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 2005; 11: 3025–31
   PubMedGoogle Scholar
• Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486–92
   PubMed Web of Science ®Google Scholar
• Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 2001; 21: 2149–53
   PubMedGoogle Scholar
• Scanlon KJ, Lu Y, Kashani-Sabet M, Ma J, Newman E. Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo. Adv Exp Med Biol 1988; 244: 127–35
   PubMedGoogle Scholar
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365–9
   PubMed Web of Science ®Google Scholar
• Johnson WG, Scholl TO, Spychala JR, Buyske S, Stenroos ES, Chen X. Common dihydrofolate reductase 19-base pair deletion allele: A novel risk factor for preterm delivery. Am J Clin Nutr 2005; 81: 664–8
   PubMed Web of Science ®Google Scholar
• Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 2000; 97: 7921–6
   PubMedGoogle Scholar
• Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10: 433–9
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Inoue Y, Nagashima N, Katsuki T, Matsumoto K, Kadowaki K, et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res 2005; 25: 3755–61
   PubMed Web of Science ®Google Scholar
• Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005; 11: 2612–9
   PubMed Web of Science ®Google Scholar
• Jensen SA, Vilmar A, Sorensen JB. Adjuvant chemotherapy in elderly patients (>or = 75 yr) completely resected for colon cancer stage III compared to younger patients: Toxicity and prognosis. Med Oncol 2006; 23: 521–31
   PubMedGoogle Scholar
• Nielsen KV, Ejlertsen BL, Poulsen TS, Mouridsen HT. Composition and methods for predicting outcome of treatment. Patent application WO2006128463 2006.
   Google Scholar
• Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721–8
   PubMed Web of Science ®Google Scholar
• Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640–7
   PubMed Web of Science ®Google Scholar
• Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 1760–70
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Seike K, Koda K, Takiguchi N, Oda K, Hasegawa R, et al. Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep 2005; 13: 621–6
   PubMedGoogle Scholar
• Jakob C, Liersch T, Meyer W, Baretton GB, Hausler P, Schwabe W, et al. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): Correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 2005; 29: 1304–9
   PubMedGoogle Scholar
• Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Hausler P, et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004; 204: 562–8
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M, Lu Y, Leong L, Haedicke K, Scanlon KJ. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer 1990; 26: 383–90
   PubMed Web of Science ®Google Scholar
• Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000; 159: 95–101
   PubMed Web of Science ®Google Scholar
• Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: A model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006; 66: 9369–73
   Google Scholar